Bone, Joint & Cancer

ResearchCentre for Endocrinology and Metabolism > Bone, Joint & Cancer

boneBone, Joint & Cancer

Research Group Head: Dr Frances Milat

Commonly associated with diseases such as osteoporosis, arthritis, most cancers of the bone and transfusion-dependent thalassemia, bone loss and reduced bone mass leaves patients at a high risk of fractures, pain, and other serious problems. We are working to identify the pathways required to build bone and limit bone destruction, as well as understand how the cells in the bone microenvironment communicate with each other. We hope these findings will assist in the identification of new ways to promote bone formation.

Research Projects:

Research Group:

Dr Fran Milat (John and Pheobe Jones Fellow) – Research Group Head
Professor Matthew Gillespie – Honorary Research Associate
Dr Vicky Kartsogiannis – Honorary Research Associate
Dr Julian Quinn – Honorary Research Associate
Dr Phillip Wong


Selected Publications:

Quinn, J.M.W., Sims, N.A., Saleh, H., Mirosa, D., Thompson, K., Bouralexis, S., Walker, E.C., Saleh, H., Martin, T.J. and Gillespie, M.T. (2008). Interleukin-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. Journal of Immunology. 181, 5720-5729

Quinn, J. M., Tam, S., Sims, N. A., Saleh, H., McGregor, N. E., Poulton, I. J., Scott, J. W., Gillespie, M. T., Kemp, B. E., van Denderen, B. J. (2010). Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB Journal. 24, 275-285

Saleh, H., Eeles, D., Hodge, J. M., Nicholson, G. C., Gu, R., Pompolo, S., Gillespie M. T. and Quinn, J.M. (2011) Interleukin-33, a target of parathyroid hormone and oncostatin M, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology. 152, 1911-1922

van der Kraan, A.G.J., Chai, R.C.C., Singh, P.P., Lang, B.J., Xu, J., Gillespie, M.T., Price, J.T. and Quinn, J.M.W. (2013). HSP90 inhibitors enhance differentiation and Microphthalmia transcription factor (MITF) activity in osteoclast progenitors. Biochemical Journal. 451, 235-244.

Wong, P., Fuller, P.J., Gillespie, M.T., Kartsogiannis, V., Strauss, B.J., Bowden, D. and Milat, F. (2013). Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporosis International. 24, 1965-1971